Short answer: GLP-1 medicines are not FDA-approved specifically to treat PCOS—now called PMOS—but some adults with PCOS/PMOS may qualify for them under their approved diabetes or chronic weight-management indications. The best current PCOS-specific evidence suggests a modest short-term reduction in body weight and BMI among people with overweight or obesity. Evidence that these medicines directly improve insulin levels, menstrual regularity, excess hair growth, fertility, or live-birth rates remains limited or uncertain.^{1, 2}

In 2026, an international consensus process selected polyendocrine metabolic ovarian syndrome (PMOS) as the new name for PCOS, and a transition period is underway.⁹ Because most searches, medication guidance, and published studies still use “PCOS,” this article uses both terms. Read more about why PCOS is now called PMOS.

What are GLP-1 medicines?

GLP-1 receptor agonists mimic some actions of glucagon-like peptide-1, a hormone involved in blood-glucose regulation, appetite, and digestion. Depending on the specific drug and indication, they can increase glucose-dependent insulin release, reduce glucagon, slow gastric emptying, and reduce appetite.

Semaglutide and liraglutide are GLP-1 receptor agonists. Tirzepatide is different: it activates both GIP and GLP-1 receptors, so it is more accurately described as a dual GIP/GLP-1 receptor agonist.

On a phone or narrow screen, swipe horizontally to view the full table.

Brand names are not interchangeable. The same active ingredient may be sold under different brands with different indications, doses, devices, and instructions. Ozempic and Mounjaro are not simply alternate names for Wegovy and Zepbound. Always follow the label and prescribing instructions for the exact product you receive.

Why are these medicines considered in PCOS/PMOS?

PCOS/PMOS can involve insulin resistance, abnormal glucose tolerance, higher cardiometabolic risk, and difficulty managing weight. These features vary widely, and PCOS/PMOS occurs at every body size. You can learn more in our guide to insulin resistance and glucose testing in PCOS/PMOS.

The 2023 International Evidence-Based PCOS Guideline says anti-obesity medicines including liraglutide and semaglutide could be considered, in addition to active lifestyle intervention, for adults with higher weight according to general-population guidelines. It also emphasizes contraception when pregnancy is possible, gradual dose escalation to reduce gastrointestinal effects, shared decision-making, the possible need for long-term treatment, weight regain after discontinuation, and the lack of long-term PCOS-specific safety data.¹

This is not a recommendation for every person with PCOS/PMOS. It means that PCOS/PMOS may be one part of a broader clinical assessment when a person otherwise meets the criteria for an approved medication.

What does the latest PCOS/PMOS evidence show?

The most current PCOS-specific systematic review and meta-analysis, published in 2026, included 11 randomized controlled trials. Compared with control treatment, adding a GLP-1 receptor agonist reduced BMI by an average of 1.38 kg/m². The reviewers rated the certainty of that evidence as low.²

The same review found insufficient or uncertain evidence for several outcomes people commonly ask about, including:

• Glucose and insulin measures
• Menstrual regularity
• Excess facial or body hair
• Quality of life and mental health
• Long-term safety and cost-effectiveness in PCOS/PMOS

A 2025 meta-analysis also reported reductions in body weight, BMI, and waist circumference across randomized PCOS trials, while highlighting small samples, short follow-up, and differences between study designs.³ An earlier phase 3 trial of liraglutide in women with obesity and PCOS found greater weight reduction than placebo over 32 weeks, but one drug-specific short-term trial cannot establish a class-wide fertility or long-term PCOS benefit.⁶

Can GLP-1 medicines regulate periods or improve fertility?

Possibly for some people, but the evidence is not strong enough to treat these medicines as fertility therapy. Changes in weight, insulin sensitivity, and energy balance can influence ovulation, and some small studies have reported cycle changes. However, the 2026 review found the evidence for menstrual regularity insufficient, and better cycle regularity is not the same as proof of improved conception, pregnancy, or live-birth rates.²

The international guideline states that anti-obesity medicines should be used for reproductive outcomes only in research settings.¹ If pregnancy is desired, care should focus on preconception health and evidence-based ovulation or fertility treatment when needed.

For anovulatory infertility in PCOS/PMOS without another infertility factor, the guideline identifies letrozole—not a GLP-1 medicine—as the first-line medication for ovulation induction.¹

There is also a practical reason to plan ahead: if ovulation becomes more regular, pregnancy may occur even when cycles were previously unpredictable. Anyone who could become pregnant should discuss contraception and a medication-stop plan before treatment begins.

Who might discuss a GLP-1 medicine with a clinician?

A clinician may consider a medicine after reviewing the approved indication, health goals, prior treatment, pregnancy plans, and potential risks. A discussion may be reasonable for an adult with PCOS/PMOS who also has an approved indication such as type 2 diabetes or who meets the criteria for chronic weight-management medication.

The decision should not be based on a PCOS diagnosis, appearance, or a single insulin value. It may include:

• Current diagnoses, glucose results, blood pressure, lipids, and other health risks
• Body-weight history and the person’s goals without weight stigma
• Pregnancy intentions and contraception
• History of gallbladder, pancreatic, kidney, gastrointestinal, thyroid, or eating-disorder concerns
• Current medicines and possible interactions
• Cost, insurance coverage, availability, and ability to continue treatment
• A plan for nutrition, physical activity, side-effect monitoring, and follow-up

What about “lean PCOS”?

PCOS/PMOS can occur at any body size. The guideline’s recommendation for anti-obesity medication applies to adults with higher weight under general weight-management criteria; evidence for GLP-1 treatment specifically in lower-weight PCOS/PMOS is very limited.^{1, 2} A lower-weight person should not be prescribed a weight-loss medicine simply because PCOS/PMOS may involve insulin resistance.

Is a GLP-1 medicine better than metformin for PCOS/PMOS?

There is no universal “better” option because the medicines have different evidence, approved uses, costs, risks, and treatment goals. Neither metformin nor a GLP-1 medicine is FDA-approved specifically for PCOS/PMOS.

The international guideline says metformin should be considered for adults with PCOS and a BMI of 25 kg/m² or higher for anthropometric and metabolic outcomes, including insulin resistance, glucose, and lipids; evidence is more limited below that BMI threshold. It says GLP-1 and other anti-obesity medicines may be considered for higher weight according to general-population guidance.¹

Metformin is an oral medicine with decades of clinical use and a different side-effect and cost profile. GLP-1-based medicines usually produce more weight loss in their approved obesity populations, but PCOS-specific head-to-head evidence remains limited. They should not be substituted for one another—or combined—without clinician oversight.

Contraception, trying to conceive, and pregnancy

GLP-1-based weight-management medicines should not be used during pregnancy. Weight loss offers no benefit during pregnancy and may cause fetal harm. If pregnancy occurs, contact the prescriber promptly rather than waiting for the next routine visit.^{4, 5}

Accidental exposure before pregnancy is recognized is not a reason to panic, but the medicine should not be continued without promptly contacting the prescriber. A 2026 observational study was somewhat reassuring overall, but it could not establish safety or rule out smaller risks.⁸

Semaglutide

The current Wegovy prescribing information advises stopping semaglutide at least two months before a planned pregnancy because of its long half-life.⁴ Planning is important even if cycles are irregular.

Tirzepatide

The current Zepbound label advises discontinuing tirzepatide when pregnancy is recognized. It does not state the same two-month preconception interval used in the Wegovy label, so ask the prescriber how far in advance to stop based on the exact medicine and clinical situation.⁵

Tirzepatide can reduce the effectiveness of oral hormonal contraceptives. The label advises switching to a nonoral contraceptive or adding a barrier method for four weeks after starting tirzepatide and for four weeks after every dose increase.⁵

Breastfeeding recommendations can differ by drug and formulation. Review the current label and discuss the benefits and risks with the prescriber and the infant’s clinician.

Common side effects, warnings, and red flags

Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, reflux, and fatigue. Slow dose escalation is commonly used to improve tolerability. Do not accelerate the schedule or take extra doses because results seem slow.^{1, 4, 5}

Important risks in current semaglutide and tirzepatide weight-management labels include pancreatitis, gallbladder disease, acute kidney injury related to dehydration, severe gastrointestinal reactions, low blood glucose when combined with certain diabetes medicines, and possible aspiration during anesthesia or deep sedation because gastric emptying may be delayed. Tell the surgical or anesthesia team that you take the medicine before any procedure.^{4, 5}

These labels carry boxed warnings about thyroid C-cell tumors observed in rodents. The medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.^{4, 5}

Contact a healthcare professional promptly for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, signs of dehydration, symptoms suggestive of gallbladder trouble, a serious allergic reaction, pregnancy, or any severe or rapidly worsening symptom. Emergency symptoms require urgent medical care.

What happens after stopping?

Weight regain is common after anti-obesity medication is stopped. In the extension of a large semaglutide obesity trial—not a PCOS-specific trial—participants regained about two-thirds of their prior weight loss during the year after treatment ended.⁷ This does not predict exactly what will happen to one person, but it supports discussing duration, affordability, side effects, pregnancy plans, and a long-term care strategy before starting.

Stopping should be coordinated with the prescriber, especially when the medicine is also treating diabetes. A follow-up plan may include nutrition support, physical activity, sleep, mental-health care, glucose monitoring, and alternative medication when appropriate.

Nutrition and muscle support during treatment

Reduced appetite and gastrointestinal symptoms can make it harder for some people to eat and drink enough. That does not mean every GLP-1 user develops a vitamin deficiency or needs the same supplement. Needs should be based on diet, symptoms, medical history, laboratory results, and professional guidance.

A practical plan may include:

• Prioritizing nutrient-dense meals and a protein source at meals and snacks
• Using smaller meals if large meals worsen nausea or fullness
• Drinking enough fluid, especially with vomiting, diarrhea, or constipation
• Increasing fiber gradually when appropriate and pairing it with adequate fluid
• Including muscle-strengthening activity when medically appropriate
• Asking a registered dietitian or clinician whether intake or laboratory monitoring suggests a specific need

For a deeper discussion, see our evidence-based guide to nutrition when appetite is reduced.

Where WrenLife products may fit

Dietary supplements do not replace GLP-1 medicines, balanced nutrition, or individualized care for PCOS/PMOS.

When appetite or food intake is reduced

WrenLife GLP-1 Support Multi+ is a two-tablet daily multivitamin and mineral supplement designed to supplement dietary intake when appetite or food intake is reduced. It is not a weight-loss product, a treatment for PCOS/PMOS, or a treatment for medication side effects. The finished formula has not been evaluated in a clinical trial.

View Multi+ ingredients and Supplement Facts →

For readers considering an inositol-containing supplement

WrenLife Hormone Health contains myo-inositol and D-chiro-inositol in a 40:1 ratio, together with the other nutrients listed on its Supplement Facts panel. It is not a treatment for PCOS/PMOS or insulin resistance. Current international PCOS guidance does not recommend a specific inositol type, dose, combination, or ratio.¹

View Hormone Health ingredients, Supplement Facts, and use information →

Before use: Multi+ contains 3,000 mcg of biotin, which can interfere with certain laboratory tests. Tell your clinician and laboratory personnel before bloodwork. Multi+ is not formulated as a prenatal and should not be combined with another full multivitamin or prenatal unless a clinician has reviewed the combined amounts. Hormone Health contains alpha-lactalbumin from milk and vitamin K2. Do not use Hormone Health if you have a milk-protein allergy, and consult a healthcare professional before use if you take warfarin or another vitamin-K antagonist. Hormone Health is not intended for use during pregnancy or breastfeeding. If you are pregnant, breastfeeding, trying to conceive, or using prescription medication—including glucose-lowering medication—review any supplement with your prescriber or pharmacist.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Questions to ask your healthcare professional

• Do I meet an FDA-approved indication for this exact medicine?
• What outcome are we treating, and how will we know whether the treatment is helping?
• How strong is the evidence for that outcome specifically in PCOS/PMOS?
• How could this medicine affect my current prescriptions or oral birth control?
• What is my plan if I want to become pregnant?
• Which symptoms should prompt a same-day call or urgent care?
• How will we monitor glucose, nutrition, side effects, and muscle health?
• What are the cost, coverage, and long-term treatment options?
• What is the plan if the medicine is ineffective, unavailable, unaffordable, or not tolerated?

Frequently asked questions

Can GLP-1 medicines help PCOS/PMOS?

They may help with short-term weight reduction in adults with PCOS/PMOS and overweight or obesity, but certainty is low and other benefits remain uncertain. PCOS/PMOS alone is not an FDA-approved indication.^{1, 2}

Is Ozempic FDA-approved for PCOS?

No. Ozempic is not FDA-approved specifically for PCOS/PMOS. Semaglutide is sold under different brands with different approved indications; the exact brand and reason for prescribing matter.

Which GLP-1 medicine is best for PCOS?

Current PCOS-specific research does not establish one best medicine for everyone. Selection should be based on an approved indication, individual goals and risks, pregnancy plans, other medicines, access, and the prescriber’s assessment.

Can semaglutide regulate periods?

Some individuals may notice cycle changes, but current randomized evidence is insufficient to conclude that semaglutide reliably regulates periods in PCOS/PMOS.²

Do GLP-1 medicines improve fertility?

They are not fertility medicines, and evidence for pregnancy or live-birth outcomes is inadequate. Ovulation can change, so contraception and pregnancy planning remain important.

Can I take one while trying to conceive?

Discuss a stop plan before trying to conceive. The Wegovy label advises stopping semaglutide at least two months before a planned pregnancy. Instructions differ by medicine, and GLP-1-based weight-management medicines should not be used during pregnancy.^{4, 5}

Does tirzepatide affect birth-control pills?

It can. The Zepbound label advises switching to a nonoral contraceptive or adding a barrier method for four weeks after treatment starts and for four weeks after each dose increase.⁵

Do GLP-1 medicines cause hair loss?

Hair loss is listed among common adverse reactions in the current Zepbound label and has been reported during weight-loss treatment.⁵ Hair shedding may have several contributors, including rapid weight change, low energy or protein intake, iron or thyroid problems, stress, and hormonal conditions. A clinician can help assess the cause rather than assuming it is the drug alone.

Will the weight return after stopping?

Regain is common after anti-obesity medication is discontinued, although the amount varies. Long-term treatment and an exit plan should be discussed before starting.^{1, 7}

The bottom line

GLP-1-based medicines may be a reasonable option for some adults with PCOS/PMOS who independently meet an approved treatment indication. The strongest PCOS-specific evidence supports modest short-term weight and BMI improvement; claims about insulin resistance, periods, fertility, hirsutism, or long-term outcomes are less certain.

A good decision is not simply “GLP-1 or no GLP-1.” It is a shared plan that defines the treatment goal, separates promising evidence from proven benefit, addresses pregnancy and contraception, monitors side effects and nutrition, and considers what happens if treatment eventually stops.

Scientific references

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463. View source
2. Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome—a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3):25–39. doi:10.1093/ejendo/lvag033. View source
3. Lin S, Deng Y, Huang J, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15:16512. doi:10.1038/s41598-025-99622-4. View source
4. U.S. National Library of Medicine. WEGOVY (semaglutide) prescribing information. DailyMed; updated June 18, 2026. View current label
5. U.S. National Library of Medicine. ZEPBOUND (tirzepatide) prescribing information. DailyMed; updated April 22, 2026. View current label
6. Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled phase 3 study. Fertil Steril. 2022;118(2):371–381. doi:10.1016/j.fertnstert.2022.04.027. View source
7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725. View source
8. Brown JP, et al. Glucagon-Like Peptide-1 Receptor Agonist Use in Early Pregnancy and Reproductive Safety: A Target Trial Emulation. Ann Intern Med. 2026. doi:10.7326/ANNALS-25-04820. View source
9. Teede HJ, Bahri Khomami M, Morman R, et al. Renaming polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: a global consensus process. Lancet. 2026;407(10545):2329–2339. doi:10.1016/S0140-6736(26)00717-8. View source

Last reviewed: July 2026. Medication indications and prescribing information can change. Confirm the current label and individualized advice with a qualified healthcare professional.